OTCMKTS:BIOAF Bioasis Technologies (BIOAF) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free BIOAF Stock Alerts $0.0040 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.0040▼$0.004050-Day Range N/A52-Week Range$0.0015▼$0.0182VolumeN/AAverage Volume200 shsMarket Capitalization$317,640.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Bioasis Technologies alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Bioasis Technologies Stock (OTCMKTS:BIOAF)Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.Read More BIOAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOAF Stock News HeadlinesMarch 21, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - BTIJanuary 9, 2024 | morningstar.comBioasis Technologies Inc 107August 1, 2023 | investing.combiOasis Technologies Inc (BTI) Earnings Dates & ReportsJune 27, 2023 | benzinga.comShort Volatility Alert: Bioasis Tech IncJune 22, 2023 | chron.comNew Haven biotech company suspending operations after failed mergerJune 21, 2023 | finanznachrichten.deBioasis Technologies Inc.: Bioasis Provides Corporate Update and Announces Suspension of OperationsMarch 23, 2023 | finance.yahoo.comBioasis Provides Update on Business OperationsJanuary 19, 2023 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022December 16, 2022 | chron.comNew Haven-based biotech company signs $5.42 million agreement to merge with British companyDecember 13, 2022 | marketwatch.comMidatech Pharma Shares Fall on Bioasis Technologies Buy, Plan to Cancel AIM ListingDecember 13, 2022 | finance.yahoo.com/C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - ResumptionsOctober 29, 2022 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022August 8, 2022 | finance.yahoo.comBioasis Technologies Inc. Announces Stock Option GrantsJune 16, 2022 | finance.yahoo.comBioasis Acquires Phase 2 Ready Rare Orphan EGF AssetsApril 26, 2022 | finance.yahoo.comBIOAF: Collaboration Arrangement with JanssenApril 11, 2022 | seekingalpha.comBioasis enters into research collaboration with Janssen for its xB3 platformApril 11, 2022 | finance.yahoo.comBioasis Enters Into Research Collaboration With JanssenJanuary 31, 2022 | finance.yahoo.comBIOAF: Third Quarter ResultsJanuary 20, 2022 | sfgate.comBiOasis: Fiscal Q3 Earnings SnapshotJanuary 20, 2022 | finance.yahoo.comBioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021January 16, 2022 | nasdaq.comBioasis Technologies Inc (BIOAF)November 3, 2021 | finance.yahoo.comBIOAF: Second Quarter UpdateOctober 28, 2021 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021August 18, 2021 | apnews.comBioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business ...August 18, 2021 | financialpost.comBioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development AdvisorSee More Headlines Receive BIOAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioasis Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today6/16/2024Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drugs, proprietaries, & sundries Sub-IndustryN/A Current SymbolOTCMKTS:BIOAF CUSIPN/A CIKN/A Webwww.bioasis.us Phone(203) 533-7082FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$30,000.00 Price / Sales10.59 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares79,410,000Free FloatN/AMarket Cap$317,640.00 OptionableNot Optionable Beta0.90 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Deborah Ann Rathjen B.Sc. (Hons.) (Age 66)FTSE, M.A.I.C.D., Ph.D., Q.C., Executive Chairman, CEO & President Comp: $152.59kMr. David P. Jenkins (Age 62)Chief Financial Officer Comp: $91.55kMr. Graeme DickDirector of Investor RelationsMr. Aaron EltonDirector of MarketingDr. Mei Mei TianVP & Head of External ResearchKey CompetitorsScripsAmericaOTCMKTS:SCRCQBactolac PharmaceuticalOTCMKTS:BTCAChina BCT Pharmacy GroupOTCMKTS:CNBIChina MedicineOTCMKTS:CHMEMcKessonNYSE:MCKView All Competitors BIOAF Stock Analysis - Frequently Asked Questions How have BIOAF shares performed in 2024? Bioasis Technologies' stock was trading at $0.0047 at the beginning of the year. Since then, BIOAF stock has decreased by 14.9% and is now trading at $0.0040. View the best growth stocks for 2024 here. How were Bioasis Technologies' earnings last quarter? Bioasis Technologies Inc. (OTCMKTS:BIOAF) announced its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). How do I buy shares of Bioasis Technologies? Shares of BIOAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BIOAF) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioasis Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioasis Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.